000 06105nam a2200445Ka 4500
001 bslw06339726
003 UtOrBLW
005 20210303085425.0
006 m d
007 cr un|||||||||
008 101115s2001 enk o 000 0 eng d
020 _a9781849500708 (electronic bk.) :
_c£86.95 ; €128.95 ; $154.95
040 _aUtOrBLW
_cUtOrBLW
050 4 _aRA410.5
_b.I58 2001
072 7 _aMBP
_2bicssc
072 7 _aMBN
_2bicssc
072 7 _aSOC023000
_2bisacsh
072 7 _aMED078000
_2bisacsh
080 _a614
082 0 4 _a338.433621
_222
245 0 0 _aInvesting in health
_h[electronic resource] :
_bthe social and economic benefits of health care innovation /
_cedited by Irina Farquhar, Kent Summers, Alan Sorkin.
260 _aBingley, U.K. :
_bEmerald,
_c2001.
300 _a1 online resource (xvii, 449 p.).
490 1 _aResearch in human capital and development,
_x0194-3960 ;
_vv. 14
505 0 _aThe frontiers of genetics and the transformation of medicine and business / Robert Field -- Outpatient prescription drug prices and insurance coverage : an analysis by therapeutic drug class and user characteristics from the 1996 medical expenditure panel survey / G. Edward Miller, John Moeller -- Pharmaceutical spending and health outcomes in the united states / Pierre-Yves Cremieux, Pierre Ouellette, Marie-Claude Meilleur, Stephanie Leong, Paul Greenberg, Howard Birnbaum -- Too many drugs? The clinical and economic value of incremental innovations / Albert Wertheimer, Richard Levy, Thomas O'Connor -- Factors affecting health services utilization in the medicare population : would providing prescription drug coverage to medicare recipients affect their use of health care resources? / Mary Cifaldi -- Estimating economic cost of HIV/AIDS-related diseases / Irina Farquhar, Alan Sorkin, Kent Summers, Earl Weir -- Estimating the social and economic benefits of pharmaceutical innovation : modeling clinical trial results in hiv disease / Kit Simpson, Eberhard Voit, Russell Goodman, Elinor Chumney -- Concomitant illnesses in patients with diabetes : mortality, morbidity, benefits of newer treatments, and individual and societal costs / Irina Farquhar, Alan Sorkin, Kent Summers, Earl Weir -- Factors influencing patient willingness to pay for diabetes disease state management programs / Jamie Bamer -- Assessment of the relationship between quality of life and willingness to pay for in vitro fertilization in patients undergoing treatment for infertility / Tina Stavinoha, Jamie Barner -- Impact of diabetes on human capital and quality of life / Kent Summers, Risa Hayes -- Energy and improved workplace productivity in depression / Ralph Swindle, Kurt Kroenke, LeeAnn Braun -- Can mental health treatment be effectively delivered in primary care? A primer for employee benefit design, decision makers, and an outcome research example / Ralph Swindle, Lisa Harris, Kurt Kroenke, Wansu Tu, X. Zhou -- The interaction of depression and smoking on workplace productivity / Michael Halpern, Zeba Khan, Anne Rentz -- Cost effectiveness in the prevention of suicide : a population approach / Lars von Knorring, Kerstin Bingefors, Lisa Ekselius, Anne-Liis von Knorring, Gunilla Olsson -- Payment effects on resource utilization and outcomes for patients with congestive heart failure / Eugene Kroch, Raj Shah, Douglas Fisher, Evan Loh, J. Sanford Schwartz.
520 _aPublic health has, for many years, been concerned with efforts to increase the efficiency of health care delivery, to measure changes in health care resource utilization and associated costs, and to link these changes to different types of interventions. These efforts, as well as collaboration between biopharmaceutical organizations, producers of medical devices, and managed care and public health organizations, have been enhanced by the opportunities created within the fast growing field of outcomes research. This volume presents studies contributing to the enhancement of the outcomes research paradigm by incorporating economic and social interactions within the health care delivery, clinical decision-making and outcomes systems. A multidisciplinary team of scientists in the fields of outcomes research, pharmacoeconomics, public health, health services research, and health economics address such complex problems as: benefits and cost of advancements in genetic technologies; methodologies for constructing health care utilization and cost estimates; and the effect of insurance type on resource utilization and health outcomes. Other studies consider both the types of drugs purchased and the prices paid, pharmaceutical spending and health outcomes, incremental advantages of newer treatments, willingness to pay measurements, disease-specific impacts on human capital and quality of life, and modelling clinical trial results. One of the most important findings in this book is the description of the role of low energy in the symptomatology of depression and its strong relationship with absenteeism, work productivity and social functioning. Another paper documents the disease-specific mortality, case-fatality and annual health care utilization in diabetics and establishes the association of respiratory conditions with elevated mortality among diabetics. The work contains other papers which provide significant results in cardiovascular, infectious, central nervous system disease areas as well as in quality of life and health outcomes measurements.
588 0 _aPrint version record
650 7 _aSocial Science
_xReference.
_2bisacsh
650 7 _aMedical
_xPublic Health.
_2bisacsh
650 7 _aHealth systems & services.
_2bicssc
650 7 _aPublic health & preventive medicine.
_2bicssc
650 0 _aMedical care
_xCoste effectiveness.
700 1 _aFarquhar, Irina.
700 1 _aSummers, Kent.
700 1 _aSorkin, Alan.
776 1 _z9780762306978
830 0 _aResearch in human capital and development ;
_vv. 14.
856 4 0 _uhttps://www.emerald.com/insight/publication/doi/10.1016/S0194-3960(2001)14
913 _1BMEbacklist
999 _c32118
_d32118